Patents by Inventor Yunho Jin

Yunho Jin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12099869
    Abstract: A scheduler, a method of operating the scheduler, and an electronic device including the scheduler are disclosed. The method of operating the scheduler configured to determine a model to be executed in an accelerator includes receiving one or more requests for execution of a plurality of models to be independently executed in the accelerator, and performing layer-wise scheduling on the models based on an idle time occurring when a candidate layer which is a target for the scheduling in each of the models is executed in the accelerator.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: September 24, 2024
    Assignees: Samsung Electronics Co., Ltd., SNU R&DB FOUNDATION
    Inventors: Seung Wook Lee, Younghwan Oh, Jaewook Lee, Sam Son, Yunho Jin, Taejun Ham
  • Publication number: 20230259747
    Abstract: A DNN accelerator system includes a plurality of accelerator nodes each including a plurality of NAND flash memories, a flash memory system (FMS) controller for controlling the plurality of NAND flash memories, and a tensor buffer, and a processor configured to generate an operation sequence of the plurality of accelerator nodes, in which a DNN model is trained in a data parallel manner using the plurality of accelerator nodes.
    Type: Application
    Filed: December 27, 2022
    Publication date: August 17, 2023
    Inventors: Jae W. Lee, Yunho Jin, Jong Hyun Bae, Gin A Sohn, Tae Jun Ham
  • Publication number: 20230143270
    Abstract: A processor-implemented method with scheduling includes: receiving one or more execution requests for a plurality of models executed independently of each other in an accelerator; predicting, for each of the plurality of models, quality of service (QoS) information corresponding to the model; and scheduling the plurality of models in units of layers of the plurality of models based on, for each of the plurality of models, either one or both of the QoS information and an idle time occurring in response to a candidate layer to be scheduled in the model being executed in the accelerator.
    Type: Application
    Filed: August 15, 2022
    Publication date: May 11, 2023
    Applicants: Samsung Electronics Co., Ltd., Seoul National University R&DB Foundation
    Inventors: Jae Wook LEE, Younghwan OH, Yunho JIN, Tae Jun HAM
  • Publication number: 20220305134
    Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
    Type: Application
    Filed: June 6, 2022
    Publication date: September 29, 2022
    Inventors: Anthony Edward BOITANO, Matthew BURGER, Susan E. CELLITTI, Michael P. COOKE, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Yunho JIN, Si Tuen LEE-HOEFLICH, HongNgoc Thi PHAM, Siew Ho SCHLEYER, Kathrin TISSOT, Tetsuo UNO, Ben WEN
  • Patent number: 11357864
    Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 14, 2022
    Assignee: Novartis AG
    Inventors: Ben Wen, Anthony E. Boitano, Matthew Burger, Susan E. Cellitti, Michael P. Cooke, Catrin Finner, Bernhard Hubert Geierstanger, Yunho Jin, Si Tuen Lee-Hoeflich, HongNgoc Thi Pham, Siew Ho Schleyer, Kathrin Tissot, Tetsuo Uno
  • Publication number: 20220114015
    Abstract: A scheduler, a method of operating the scheduler, and an electronic device including the scheduler are disclosed.
    Type: Application
    Filed: March 9, 2021
    Publication date: April 14, 2022
    Applicants: Samsung Electronics Co., Ltd, SNU R&DB FOUNDATION
    Inventors: Seung Wook LEE, Younghwan OH, Jaewook LEE, Sam SON, Yunho JIN, Taejun HAM
  • Patent number: 10787480
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: September 29, 2020
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Patent number: 10604547
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: March 31, 2020
    Assignee: Novartis AG
    Inventors: Matthew T. Burger, Yunho Jin, Tetsuo Uno
  • Publication number: 20200024311
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.e.
    Type: Application
    Filed: September 18, 2019
    Publication date: January 23, 2020
    Inventors: Matthew T. Burger, Yunho Jin, Tetsuo Uno
  • Publication number: 20190382441
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: June 12, 2019
    Publication date: December 19, 2019
    Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
  • Patent number: 10464969
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: November 5, 2019
    Assignee: Novartis AG
    Inventors: Matthew T. Burger, Yunho Jin, Tetsuo Uno
  • Publication number: 20190321483
    Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
    Type: Application
    Filed: December 19, 2017
    Publication date: October 24, 2019
    Inventors: Ben WEN, Anthony E. BOITANO, Matthew BURGER, Susan E. CELLITTI, Michael P. COOKE, Catrin FINNER, Bernhard Hubert GEIERSTANGER, Yunho JIN, Si Tuen LEE-HOEFLICH, HongNgoc Thi PHAM, Siew Ho SCHLEYER, Kathrin TISSOT, Tetsuo UNO
  • Patent number: 10392421
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: April 24, 2018
    Date of Patent: August 27, 2019
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang
  • Publication number: 20190194315
    Abstract: This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments, particularly antibody drug conjugates comprising anti-P-cadherin antibodies conjugated to auristatin analogs. The invention also relates to methods of treating cancer using the antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
    Type: Application
    Filed: June 17, 2016
    Publication date: June 27, 2019
    Applicant: Novartis AG
    Inventors: Tinya ABRAMS, Steven Bruce COHEN, Joseph Anthony D'Alessio, Jason Damiano, Clemens Durr, Bernhard Hubert GEIERSTANGER, Qi-Ying HU, Thomas HUBER, Hidetomo IMASE, Yunho JIN, Daniel MENEZES, Kathy MILLER, Morvarid MOHSENI, Weijia OU, Katherine RENDAHL, Tetsuo UNO, Yongqin WAN, Xing WANG
  • Publication number: 20190144504
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (A), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Application
    Filed: May 3, 2017
    Publication date: May 16, 2019
    Inventors: Matthew T. Burger, Yunho Jin, Tetsuo Uno
  • Publication number: 20180244717
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: April 24, 2018
    Publication date: August 30, 2018
    Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Yunho JIN, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG
  • Patent number: 9988420
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: June 5, 2018
    Assignee: Novartis AG
    Inventors: Bernhard Hubert Geierstanger, Jan Grunewald, Weijia Ou, Tetsuo Uno, Yongqin Wan, Xing Wang, Yunho Jin
  • Patent number: 9938323
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 10, 2018
    Assignee: Novartis AG
    Inventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
  • Publication number: 20170355731
    Abstract: The invention disclosed herein relates to cytotoxic cyclic peptides of Formula (I), methods of inhibiting RNA polymerase with such cyclic peptides, immunoconjugates comprising such cyclic peptides (i.
    Type: Application
    Filed: November 5, 2015
    Publication date: December 14, 2017
    Inventors: Jan Grunewald, Yunho Jin, Weijia Ou, Tetsuo Uno
  • Publication number: 20160311853
    Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.
    Type: Application
    Filed: December 17, 2014
    Publication date: October 27, 2016
    Applicant: NOVARTIS AG
    Inventors: Bernhard Hubert GEIERSTANGER, Jan GRUNEWALD, Weijia OU, Tetsuo UNO, Yongqin WAN, Xing WANG, Yunho JIN